Top Markets
#1 DogBull DogBull +108.53%
#2 MarsCoin MarsCoin +84.53%
#3 Siacoin Siacoin +54.45%
#4 ADO Protocol ADO Protocol +52.61%
#5 The Bitcoin Bull The Bitcoin Bull +28.19%
#6 Ontology Gas Ontology Gas +26.26%
#7 Apertum Apertum +16.17%
#8 Arowana Arowana +12.72%
#9 Pons Pons +12.09%
#10 Useless Coin Useless Coin +11.98%
Coin of the day
DogBull DogBull
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT
Classement en actions #15062
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Prix de l'action
$4.48
Dernière synchronisation: 2026-08-31
Capitalisation boursière
$375.37M
Changement (1 jour)
-0.06%
Changement (1 an)
-61.30%
Pays
US
Échange EyePoint Pharmaceuticals, Inc. (EYPT)

Catégorie

Healthcare
Historique du prix de l'action pour EyePoint Pharmaceuticals, Inc. (EYPT)
Prix de clôture le plus élevé : $8.36 le 2026-08-01

Prix de clôture le plus bas : $379.87 le 2005-01-01
Historique du prix de l'action de EyePoint Pharmaceuticals, Inc. de 2005 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -19.87%
2025 116.50%
2024 -60.60%
2023 566.15%
2022 -78.68%
2021 183.07%
2020 -66.89%
2019 -27.25%
2018 80.00%
2017 -34.90%
2016 -56.63%
2015 -4.94%
2014 30.94%
2013 151.21%
2012 5.04%
2011 -78.05%
2010 47.76%
2009 269.05%
2008 -68.77%
2007 -56.96%
2006 -61.72%
2005 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $544.38 39.22%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 45.21%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.37 -11.93%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.80 476.17%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $747.04 4.70%
CH